[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
At VEITHsymposium, Philips will launch PVDandMe.com, a new patient education website providing resources on peripheral vascular disease (PVD) to help patients improve their quality of life.
One in every 20 Americans over the age of 50 has peripheral artery disease (PAD), a common peripheral vascular disease. If left untreated, PAD can become a serious condition linked to severe complications and an increased risk of a heart attack and stroke . Since peripheral vascular disease often has few symptoms, the need for understanding of the condition and integrated solutions offering personalized care is extremely critical. Philips’ new patient website provides information about common peripheral vascular disease conditions, signs, symptoms, causes and risk factors. Philips also has launched a complementary PVD site for healthcare providers, Philips.com/PVDresources, with tools to help clinicians establish an office-based laboratory, improving practice workflow and educating colleagues.
“The new Philips unbranded, patient-focused PVD website is a rich resource to aid patients with peripheral vascular disease in understanding their condition to seek treatment to improve their quality of life,” said Dr. Raghu Kolluri, MS, MD, RVT, System Medical Director of Vascular Medicine at OhioHealth. “By offering extensive information from treatment options to the physician locator tool, Philips is helping patients better understand their diagnosis and seek appropriate treatment.”
At VEITH, Philips will showcase its leading portfolio of interventional imaging systems, devices, software, and services. With its recent acquisition of Spectranetics in August 2017, Philips’ expanded range of therapy devices for peripheral vascular disease at this year’s symposium will include:
- Azurion is the next generation image-guided therapy platform, which enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.
- Stellarex drug-coated balloon delivers top-tier clinical results for common to complex patients. As the only commercially available drug-coated balloon with two reported randomized controlled trials, Stellarex has demonstrated durability with consistently high patency rates in a wide range of patients.
- The Phoenix atherectomy system, which combines the benefits of existing atherectomy systems, delivers a unique, hybrid  atherectomy option to help physicians tailor the treatment approach for each patient.
- SymphonySuite is Philips’ comprehensive program that includes a robust set of tools to support efforts in opening, growing and maintaining office based lab solutions.
“Our recent acquisition of Spectranetics has accelerated our expansion into therapy devices, complementing our image-guided therapy portfolio that is designed to help clinicians perform efficient and effective treatments,” said Christopher Barys, Image Guided Therapy Devices Business Leader for Philips. “Additionally, the launch of the patient resource and clinician webpage demonstrates how we are working to improve patient care and further our goal to help clinicians decide, guide, treat and confirm the right therapies for their patients.”
See the calendar of events, as well as general information about Philips’ presence at the show here. Visit the Philips and Philips Spectranetics booths (#426 and #308) and the Philips Pavilion in the Nassau suite to experience innovative solutions that deliver the full health continuum in the vascular space. Follow the #VEITH17 conversation on @PhilipsLiveFrom throughout the event.
 National Institutes of Health, Facts About Peripheral Arterial Disease (P.A.D.), NHLBI.NIH.gov, September 2017
 Directional cutting ability only available with Phoenix 2.4mm deflecting catheter